메뉴 건너뛰기




Volumn 59, Issue 2, 2008, Pages 227-231

Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer

Author keywords

Docetaxel; Epidermal growth factor; Erlotinib; Gefitinib; Non small cell lung cancer; Response; Survival

Indexed keywords

DOCETAXEL; ERLOTINIB; GEFITINIB;

EID: 38649101239     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.08.027     Document Type: Article
Times cited : (15)

References (10)
  • 1
    • 38649132651 scopus 로고    scopus 로고
    • GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. Lyon: IARC Press; 2001.
    • GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. Lyon: IARC Press; 2001.
  • 3
    • 0034069620 scopus 로고    scopus 로고
    • Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
    • Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18 10 (2000) 2095-2103
    • (2000) J Clin Oncol , vol.18 , Issue.10 , pp. 2095-2103
    • Shepherd, F.A.1    Dancey, J.2    Ramlau, R.3    Mattson, K.4    Gralla, R.5    O'Rourke, M.6
  • 4
    • 0034095853 scopus 로고    scopus 로고
    • Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 non-small cell lung cancer study group
    • Fossella F.V., DeVore R., Kerr R.N., Crawford J., Natale R.R., Dunphy F., et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 non-small cell lung cancer study group. J Clin Oncol 18 12 (2000) 2354-2362
    • (2000) J Clin Oncol , vol.18 , Issue.12 , pp. 2354-2362
    • Fossella, F.V.1    DeVore, R.2    Kerr, R.N.3    Crawford, J.4    Natale, R.R.5    Dunphy, F.6
  • 5
    • 2442661845 scopus 로고    scopus 로고
    • Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
    • Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22 9 (2004) 1589-1597
    • (2004) J Clin Oncol , vol.22 , Issue.9 , pp. 1589-1597
    • Hanna, N.1    Shepherd, F.A.2    Fossella, F.V.3    Pereira, J.R.4    De Marinis, F.5    von Pawel, J.6
  • 7
    • 0012381722 scopus 로고    scopus 로고
    • Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 trial)
    • [corrected]
    • Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 trial). J Clin Oncol 21 12 (2003) 2237-2246 [corrected]
    • (2003) J Clin Oncol , vol.21 , Issue.12 , pp. 2237-2246
    • Fukuoka, M.1    Yano, S.2    Giaccone, G.3    Tamura, T.4    Nakagawa, K.5    Douillard, J.Y.6
  • 8
    • 0142055937 scopus 로고    scopus 로고
    • Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial
    • Kris M.G., Natale R.B., Herbst R.S., Lynch Jr. T.J., Prager D., Belani C.P., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290 16 (2003) 2149-2158
    • (2003) JAMA , vol.290 , Issue.16 , pp. 2149-2158
    • Kris, M.G.1    Natale, R.B.2    Herbst, R.S.3    Lynch Jr., T.J.4    Prager, D.5    Belani, C.P.6
  • 9
    • 27544503230 scopus 로고    scopus 로고
    • Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
    • Thatcher N., Chang A., Parikh P., Rodrigues P.J., Ciuleanu T., von Pawel J., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366 9496 (2005) 1527-1537
    • (2005) Lancet , vol.366 , Issue.9496 , pp. 1527-1537
    • Thatcher, N.1    Chang, A.2    Parikh, P.3    Rodrigues, P.J.4    Ciuleanu, T.5    von Pawel, J.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.